MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
On June 8, 2026, in La Jolla, California, MediciNova, Inc., a biopharmaceutical company listed on NASDAQ (MNOV) and the Tokyo Stock Exchange (Code Number: 4875), announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office. This notice pertains to a patent application involving the utilization of ibudilast (MN-166) alongside an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for treating glioblastoma. The allowance of this patent is anticipated to reinforce the company's intellectual property position as it advances its strategy for developing combination therapies.